- Home
- KWE vs GLMD Comparison
KWE vs GLMD Comparison
Compare KWE & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KWE
- GLMD
- Stock Information
- Founded
- KWE 2017
- GLMD 2000
- Country
- KWE Canada
- GLMD Israel
- Employees
- KWE N/A
- GLMD N/A
- Industry
- KWE
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- KWE
- GLMD Health Care
- Exchange
- KWE Nasdaq
- GLMD Nasdaq
- Market Cap
- KWE 3.1M
- GLMD 3.0M
- IPO Year
- KWE N/A
- GLMD 2014
- Fundamental
- Price
- KWE $10.76
- GLMD $1.81
- Analyst Decision
- KWE
- GLMD Hold
- Analyst Count
- KWE 0
- GLMD 1
- Target Price
- KWE N/A
- GLMD N/A
- AVG Volume (30 Days)
- KWE 3.0M
- GLMD 364.3K
- Earning Date
- KWE 08-15-2025
- GLMD 05-22-2025
- Dividend Yield
- KWE N/A
- GLMD N/A
- EPS Growth
- KWE N/A
- GLMD N/A
- EPS
- KWE N/A
- GLMD N/A
- Revenue
- KWE $2,115,849.00
- GLMD N/A
- Revenue This Year
- KWE N/A
- GLMD N/A
- Revenue Next Year
- KWE N/A
- GLMD N/A
- P/E Ratio
- KWE N/A
- GLMD N/A
- Revenue Growth
- KWE 121.88
- GLMD N/A
- 52 Week Low
- KWE $3.86
- GLMD $1.15
- 52 Week High
- KWE $116.99
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- KWE 63.32
- GLMD 61.13
- Support Level
- KWE $7.16
- GLMD $1.63
- Resistance Level
- KWE $15.37
- GLMD $1.94
- Average True Range (ATR)
- KWE 1.94
- GLMD 0.12
- MACD
- KWE 0.32
- GLMD 0.01
- Stochastic Oscillator
- KWE 55.72
- GLMD 69.77
About KWE KWESST Micro Systems Inc.
KWESST Micro Systems Inc develops and commercializes next-generation tactical systems. The company offers breakthrough technology in lethal and non-lethal systems with broad application, including law enforcement and personal defence, modernized digitization of tactical forces for shared situational awareness and targeting, and counter-measures against threats such as drones, lasers and electronic detection.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.